- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02977429
Evaluation of Pcv-aCO2 in the Fluid Treatment of Abdominal Tumor Patients After Surgery
Clinical Study of Central Venous-to-Arterial Carbon Dioxide Difference(Pcv-aCO2) in the Evaluation of Fluid Therapy for Postoperative Patients With Abdominal Cancer
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
- Confirmed that Pcv-aCO2 is suitable for the guidance of early fluid therapy and the evaluation of the prognosis of patients with abnormal hemodynamics after abdominal tumor surgery, and is expected to be a new monitoring index to improve the therapeutic efficacy of this kind of patients.
- Pcv-aCO2 effectively reflected the improvement of tissue and organ microcirculation disorder through the individual goal target treatment to guide the fluid resuscitation in the hemodynamic instability patients.
- Research of the correlation between Pcv-aCO2 and the organ function in patients with abnormal hemodynamics after operation.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Tianjin
-
Tianjin, Tianjin, Chine, 300060
- Recrutement
- Tianjin Medical University Cancer Institute and Hospital
-
Contact:
- Wanhua Wang, director
- Numéro de téléphone: 1021 23340123
- E-mail: Wanhua_Wang1962@outlook.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Acute physiology and chronic health score system II (APACHE II) score ≥10;
- Hemodynamic abnormalities post-operation (a. systolic blood pressure<90mmHg, or descent by basic blood pressure for more than 40mmHg. b. pulse pressure <20mmHg, c. urine volume <0.5ml/Kg/hr, d. heart rate >100 / min, e.Central Venous Pressure(CVP) <5mmHg, f. blood lactic acid >2.7mmol/L, meet any one above).
- Age ≥ 18 years, which is expected to stay in ICU for 5 days or longer;
- Patients themselves or their authorized clients agree to participate in clinical trials and signed informed consent.
Exclusion Criteria:
- age <18 years;
- without improvement in respiratory system disease or chronic obstructive pulmonary disease with Forced expiratory volume in one second (FEV1) <50%;
- lobectomy and pneumonectomy;
- death within 24 after treatment;
- patients with severe organ dysfunction;
- pregnant or lactating women;
- the patients did not sign informed consent;
- any factors that may be expected to increase the risk of patients or other factors that may interfere with the results of clinical trials.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Comparateur actif: standard group
The patients with ScvO2 ≥ 70% will receive the conventional fluid therapy.than collect the data of ScvO2 and Pcv-aCO2: ScvO2≥70%,and furthermore, Pcv-aCO2 is divided into "≤6mmHg" and ">6mmHg" |
The patients with ScvO2 ≥ 70% will receive the conventional fluid therapy.
|
Comparateur factice: control group
The patients with ScvO2 <70% will receive the standardized fluid therapy for 6 hours.than collect the data of ScvO2 and Pcv-aCO2: ScvO2<70%,and furthermore, Pcv-aCO2 is divided into "≤6mmHg" and ">6mmHg" |
The patients with ScvO2 <70% will receive the standardized fluid therapy for 6 hours.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
The change of Pcv-aCO2
Délai: fluid resuscitation for 6 hours, 12 hours and 24 hours
|
The change of Pcv-aCO2 (mmHg) after fluid resuscitation for 6 hours, 12 hours and 24 hours respectively.
|
fluid resuscitation for 6 hours, 12 hours and 24 hours
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
The treatment success rate in different groups
Délai: Twenty-eighth days after admission
|
Collect the index of treatment success rate(%) of patients in different groups.
|
Twenty-eighth days after admission
|
The 28 day mortality in different groups
Délai: Twenty-eighth days after admission
|
Collect the index of 28 day mortality(%) of patients in different groups.
|
Twenty-eighth days after admission
|
The hospitalization course in different groups
Délai: Twenty-eighth days after admission
|
Collect the index of hospitalization course(days) of patients in different groups.
|
Twenty-eighth days after admission
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
The change of Central Venous Oxygen Saturation (ScvO2)
Délai: fluid resuscitation for 6 hours, 12 hours and 24 hours
|
The change of Central venous oxygen saturation (ScvO2, %)after fluid resuscitation for 6 hours, 12 hours and 24 hours respectively.
|
fluid resuscitation for 6 hours, 12 hours and 24 hours
|
The change of hemoglobin (Hb)
Délai: fluid resuscitation for 6 hours, 12 hours and 24 hours
|
The change of hemoglobin (Hb, g/L) after fluid resuscitation for 6 hours, 12 hours and 24 hours respectively.
|
fluid resuscitation for 6 hours, 12 hours and 24 hours
|
The change of blood lactic acid (Lac)
Délai: fluid resuscitation for 6 hours, 12 hours and 24 hours
|
The change of blood lactic acid (Lac, mmol/L) after fluid resuscitation for 6 hours, 12 hours and 24 hours respectively.
|
fluid resuscitation for 6 hours, 12 hours and 24 hours
|
The change of Cardiac Index (CI)
Délai: fluid resuscitation for 6 hours, 12 hours and 24 hours
|
The change of Cardiac Index (CI, L/(min•m^2)) after fluid resuscitation for 6 hours, 12 hours and 24 hours respectively.
|
fluid resuscitation for 6 hours, 12 hours and 24 hours
|
The Oxygen Supply status (DO2) in different groups
Délai: fluid resuscitation for 6 hours, 12 hours and 24 hours
|
Collect the index of oxygen supply (DO2, ml/(min•m^2)) after fluid resuscitation for 6 hours, 12 hours and 24 hours respectively.
|
fluid resuscitation for 6 hours, 12 hours and 24 hours
|
The Oxygen Consumption (VO2) in different groups
Délai: fluid resuscitation for 6 hours, 12 hours and 24 hours
|
Collect the index of oxygen consumption (VO2, ml/(min•m^2)) after fluid resuscitation for 6 hours, 12 hours and 24 hours respectively.
|
fluid resuscitation for 6 hours, 12 hours and 24 hours
|
Collaborateurs et enquêteurs
Les enquêteurs
- Directeur d'études: Wanhua Wang, director, Tianjin Medical University Cancer Institute and Hospital
Publications et liens utiles
Publications générales
- Jones AE, Shapiro NI, Trzeciak S, Arnold RC, Claremont HA, Kline JA; Emergency Medicine Shock Research Network (EMShockNet) Investigators. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA. 2010 Feb 24;303(8):739-46. doi: 10.1001/jama.2010.158.
- Futier E, Robin E, Jabaudon M, Guerin R, Petit A, Bazin JE, Constantin JM, Vallet B. Central venous O(2) saturation and venous-to-arterial CO(2) difference as complementary tools for goal-directed therapy during high-risk surgery. Crit Care. 2010;14(5):R193. doi: 10.1186/cc9310. Epub 2010 Oct 29.
- Pope JV, Jones AE, Gaieski DF, Arnold RC, Trzeciak S, Shapiro NI; Emergency Medicine Shock Research Network (EMShockNet) Investigators. Multicenter study of central venous oxygen saturation (ScvO(2)) as a predictor of mortality in patients with sepsis. Ann Emerg Med. 2010 Jan;55(1):40-46.e1. doi: 10.1016/j.annemergmed.2009.08.014. Epub 2009 Oct 25.
- Harilall Y, Adam JK, Biccard BM, Reddi A. Correlation between cerebral tissue and central venous oxygen saturation during off-pump coronary bypass graft surgery. Perfusion. 2011 Mar;26(2):83-90. doi: 10.1177/0267659110387846. Epub 2010 Nov 15.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- bc2016032
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Infection abdominale
-
Chang Wei-JungComplétéPneumonie | Abcès intra-abdominal après intervention | Fuite | Opération Blessure; Infection
-
Odense University HospitalComplétéInfection de la plaie | Intraabdominal AbscessDanemark
-
BayerComplétéAbcès intra-abdominal | Péritonite secondaireChine
-
Wyeth is now a wholly owned subsidiary of PfizerComplété
-
Silvia M. Pinango L.Merck Sharp & Dohme LLCComplétéINFECTION DU SITE CHIRURGICAL
-
Unity Health TorontoRecrutementPéritonite | Abcès abdominal | Blessure abdominale | Traumatisme abdominal | Septicémie abdominale | Anévrisme abdominal | Syndrome du compartiment abdominal | Infection abdominaleCanada
-
Duke UniversityRecrutementÉtat septique | Opération | Infection intra-abdominale | Régime alimentaire, santé | Alimentation entérale | Soins intensifs | La nutrition | Traumatisme abdominal | Aliments | Intestin ischémique | Vasculaire | Traumatisme abdominal pénétrant | OralÉtats-Unis
-
Wyeth is now a wholly owned subsidiary of PfizerComplétéCholécystite | Appendicite | Diverticulite | Abcès intra-abdominal | Infection intra-abdominale | PéritoniteItalie, Espagne, Chine, France, Suisse, Australie, Danemark, Finlande, Allemagne, Grèce, Hong Kong, Inde, Philippines, Le Portugal, Arabie Saoudite, Afrique du Sud, Taïwan, Turquie, Royaume-Uni
-
PfizerRetiréCholécystite | Appendicite | Péritonite | Infections des plaies | Abcès intra-abdominal
-
Wake Forest University Health SciencesComplétéTraumatisme abdominal contondantÉtats-Unis
Essais cliniques sur conventional fluid therapy
-
University of California, San FranciscoNational Heart, Lung, and Blood Institute (NHLBI); National Institute of Nursing...ComplétéInsuffisance cardiaque, congestiveÉtats-Unis
-
Nanogen, Inc.Centers for Disease Control and PreventionSuspendu
-
Nanogen, Inc.Suspendu
-
Medical University of South CarolinaNational Institute on Deafness and Other Communication Disorders (NIDCD)Actif, ne recrute pasAccident vasculaire cérébral | Aphasie | Aphasie Non FluentÉtats-Unis
-
Columbia UniversityRésilié
-
NeuroTronik Inc.InconnueInsuffisance cardiaque | Insuffisance cardiaque aiguëParaguay
-
Insel Gruppe AG, University Hospital BernRecrutement
-
NeuroTronik Inc.InconnueInsuffisance cardiaque aiguëPanama
-
University of Applied Sciences and Arts of Southern...Vrije Universiteit Brussel; Universiteit Antwerpen; THIM - die internationale...ComplétéEn bonne santéSuisse
-
University of Alabama at BirminghamComplétéAccident vasculaire cérébral | Parésie du membre supérieur | AVC (Accident Cérébrovasculaire)États-Unis